2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

The 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology will offer valuable information on the multidisciplinary treatment approach for thoracic malignancies. This multidisciplinary meeting will promote interaction between the surgery, medical oncology and radiation oncology disciplines to achieve the best possible outcome for thoracic cancer patients. The meeting will also bring together physician specialists from around the world for interdisciplinary discussions on the latest research and state-of-the-art care for thoracic cancers.

nab-Paclitaxel Improves Overall Response Rate, Reduces Neuropathy in Patients with Advanced Non-Small-Cell Lung Cancer Regardless of Histology; Elderly Also Benefit

0.50 / AMA PRA Category 1 Credit(s)TM
Compared with solvent-based paclitaxel, albumin-bound nab-paclitaxel exhibits 10-fold higher mean Cmax of free paclitaxel and preclinical models have shown higher drug concentration to tumors and enhanced cell transport.
 

Crizotinib Benefits in NSCLC Explored, Including in Patients with ROS1 Gene Rearrangement and with Ablative Local Therapy

0.50 / AMA PRA Category 1 Credit(s)TM
Updated results from the ongoing global phase 2 study with crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer (NSCLC).
 

Feasibility, Cost, Potential Impact of Genomic Testing for Lung Cancer in the Clinic

0.50 / AMA PRA Category 1 Credit(s)TM
Rapidly evolving sequencing technologies characterizing the cancer genome have shown that not only do germline and somatic alterations in DNA mediate genesis and progression of cancer, but they also are clinically important as diagnostic markers and therapeutic targets.
 

Afatinib 'Clinically Relevant' First-Line Treatment Option for EGFR-Mutation Positive Lung Adenocarcinoma

0.50 / AMA PRA Category 1 Credit(s)TM
LUX-Lung 3, the largest prospective trial in patients with EGFR-mutation–positive advanced adenocarcinoma of the lung and the first pivotal trial in Asian and non-Asian patients with EGFR mutations, found afatinib significantly prolonged progression-free survival (PFS).
 

Future of Lung Cancer Screening Includes Risk Prediction Models, Biomarkers

0.50 / AMA PRA Category 1 Credit(s)TM
Low-dose CT screening may benefit individuals at an increased risk for lung cancer; however, uncertainty exists about the potential harms of screening and the generalizability of the results.
 

Role of Radiotherapy Delineated in Treatment of Patients with Non-Small-Cell Lung Cancer

0.50 / AMA PRA Category 1 Credit(s)TM
High-dose radiation therapy does not improve overall survival (OS) versus a standard radiotherapy dose in patients with locally advanced non−small-cell lung cancer (NSCLC); however, intensity modulated radiotherapy (IMRT) may lead to a better OS rate in patients with stage III disease.
 

Targeting KRAS Mutant Tumors, Novel Therapies for Non-Small-Cell Lung Cancer

0.50 / AMA PRA Category 1 Credit(s)TM
KRAS is the most common driver mutation observed in lung cancer. Discovered in the 1980s, KRAS mutations were initially stereotyped in the literature as occurring primarily in heavy smokers.
 

From Best Supportive Care to Targeted Therapies: Evolving Care for Patients with Advanced Non-Small-Cell Lung Cancer

0.50 / AMA PRA Category 1 Credit(s)TM
Patients and their families often have a limited understanding of their illness and an inaccurate view of their prognosis; and patients face difficult decisions about their cancer treatment and end-of-life care. Yet, with increasing use of personalized therapy, survival can only increase.
 
Clinical Trials Database
Quickly locate frequently updated trials by cancer type, stage, location and more.

Click here to go to the Clinical Trials Database page.

Gastric Cancer Learner Survey
We are reaching out and asking that you participate in a survey that will help us understand your educational needs on the topic of Gastric Cancer.

Click here to go to the Gastric Cancer Learner Survey.

Diffuse Large B-Cell Lymphoma Learner Survey
We are reaching out and asking that you participate in a survey that will help us understand your educational needs on the topic of Diffuse Large B-Cell Lymphoma.

Click here to go to the Diffuse Large B-Cell Lymphoma Learner Survey.



Home | Browse By Disease | Browse By Specialty | Browse By Profession | About HME | Contact Us | Web Support

© 2013 Haymarket Media, Inc.

Your use of this website constitutes acceptance of Haymarket Medical Education's Privacy Policy and Terms & Conditions

Haymarket Medical Education